Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: The need for clinical trials

Renal Failure

Volumn 32, Issue 5, 2010, Pages 642-646

  Ahmed, Mohamed H ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chronic renal failure; Dyslipidemia; Hyperphosphatemia; Kidney; Niacin

Indexed keywords

CHOLESTEROL ACYLTRANSFERASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR; NICOTINAMIDE; NICOTINIC ACID; PLACEBO; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR A1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LIPID METABOLISM; MORTALITY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEINURIA; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANTILIPEMIC AGENTS; CLINICAL TRIALS AS TOPIC; DYSLIPIDEMIAS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; NIACIN;

EID: 77952968332     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860221003753323     Document Type: Article

References (19)

1. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005;16(2):529-538.
2. Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol. 2004;38(5):405-416.
3. Tonelli M, Keech A, Shepherd J, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. 2005;16(12):3748- 3754.
4. Jardine AG, Fellstrom B, Logan JO, et al. Cardiovascular risk and renal transplantation: Post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) study. Am J Kidney Dis. 2005;46(3):529-536.
5. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361(22):2113- 2122.
6. Vosper H. Niacin: A re-emerging pharmaceutical for the treatment of dyslipidemia. Br J Pharmacol. 2009;158(2):429-441.
7. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis. 2009;202(1):68-75.
8. Cho KH, Kim HJ, Kamanna VS, Vaziri ND. Niacin improves renal lipid metabolism and slows progression in chronic kidney disease. Biochim Biophys Acta. 2010;1800(1):6-15.
9. Cho KH, Kim HJ, Rodriguez-Iturbe B, Vaziri ND. Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure. Am J Physiol Renal Physiol. 2009;297(1):F106-F113.
10. Restrepo Valencia CA, Cruz J. Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia. Nefrologia. 2008;28(1):61-66.
11. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-2218.
12. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44(5 Suppl. 2):34-38.
13. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520-528.
14. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(4):1131-1138.
15. Young DO, Cheng SC, Delmez JA, Coyne DW. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int. 2009;29(5):562-567.
16. Muller D, Mehling H, Otto B, et al. Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol. 2007;2(6):1249-1254.
17. Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RN. Extended release nicotinic acid - A novel oral agent for phosphate control. Int Urol Nephrol. 2006;38(1):171-174.
18. Takahashi Y, Tanaka A, Nakamura T, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int. 2004;65(3):1099-1104.
19. Musso CG, Reynaldi MJ, Aparicio C, Frydenlund S, Imperiali N, Algranati L. Hyperphosphatemia and nicotinic acid in peritoneal dialysis patients. Int Urol Nephrol. 2008;40(1):229-230.